前列腺癌患者睾酮替代治疗的安全性研究进展

摘要
图/表
参考文献(28)
相关文章 (15)

全文: PDF (0 KB) HTML (34 KB)
输出: BibTeX | EndNote (RIS)

摘要男性性腺功能减退症是由于雄激素缺乏引起的一种临床综合征，睾酮替代治疗（TRT）是其首选治疗方法。但对于既往有前列腺癌病史的患者，TRT的应用一直存在争议。近年来，文献报道了不同阶段前列腺癌患者接受TRT的安全性研究，包括癌前病变期，主动监测、根治性治疗后及进展期前列腺癌。本文回顾这些文献并对TRT在前列腺癌患者中应用的安全性研究进展进行综述。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	汪奇波
	朱绍兴

关键词 ：前列腺癌, 性腺功能减退症, 睾酮, 替代治疗

Abstract：Hypogonadism in men is a clinical syndrome caused by androgen deficiency, for whom testosterone replacement therapy (TRT) is the preferred treatment.However, the use of TRT has been controversial in patients with a previous history of prostate cancer.In recent years, studies on the safety of TRT in patients with prostate cancer at different stages have been reported, including pre-cancerous stage, active surveillance, post-radical treatment and advanced prostate cancer.This article reviews the literatures and the progress in the application safety of TRT in patients with prostate cancer.

Key words： Prostate cancer Hypogonadism Testosterone Replacement therapy

基金资助:浙江省自然科学基金资助项目（LY16H160034）

通讯作者: 朱绍兴（1967-），男，云南镇雄人，博士，主任医师，研究方向：泌尿系肿瘤诊治

作者简介: 汪奇波（1992-），男，浙江杭州人，硕士，研究方向：泌尿系肿瘤诊治

引用本文:

汪奇波；朱绍兴. 前列腺癌患者睾酮替代治疗的安全性研究进展[J]. 中国当代医药, 2020, 27(8): 16-18.
WANG Qi-bo； ZHU Shao-xing. Research progress on the safety of testosterone replacement therapy in patients with prostate cancer. 中国当代医药, 2020, 27(8): 16-18.

链接本文:

http://dangdaiyiyao.com/CN/ 或 http://dangdaiyiyao.com/CN/Y2020/V27/I8/16

[3]	J.Lisa TENOVER.老年男性的睾酮替代疗法[J].中华男科学，2001，7（3）：141-146.
[26]	NguyenTM，PastuszakAW.Testosteronetherapyamongprostate cancer survivors[J].Sex Med Rev，2016，4（4）：376-388.
[1]	Wang C，Nieschlag E，Swerdloff R，et al.Investigation，treatment and monitoring of late-onset hypogonadism in males：ISA，ISSAM，EAU，EAA and ASA recommendations[J].Eur J Endocrinol，2008，159（5）：507-514.
[2]	Glina S，Rivero MA，Morales A，et al.Studies on prostatic cancer I.The effect of castration，of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate by Charles Huggins and Clarence V.Hodges[J].J Sex Med，2010，7（2 Pt 1）：640-644.
[4]	Hoffman MA，DeWolf WC，Morgentaler A.Is low serum free testosterone a marker for high grade prostate cancer?[J].J Urol，2000，163（3）：824-827.
[5]	García-Cruz E，Piqueras M，Huguet J，et al.Low testosterone levels are related to poor prognosis factors in men with prostate cancer prior to treatment[J].BJU Int，2012，110（11 Pt B）：E541-546.
[6]	Kim HJ，Kim BH，Park CH，et al.Usefulness of preoperative serum testosterone as a predictor of extraprostatic extension and biochemical recurrence[J].Korean J Urol，2012，53（1）：9-13.
[7]	Massengill JC，Sun L，Moul JW，et al.Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy[J].J Urol，2003，169（5）：1670-1675.
[8]	Merrimen JL，Jones G，Hussein SA，et al.A model to predict prostate cancer after atypical findings in initial prostate needle biopsy[J].J Urol，2011，185（4）：1240-1245.
[9]	Rhoden EL，Morgentaler A.Testosterone replacement therapy in hypogonadal men at high risk for prostate cancer：results of 1 year of treatment in men with prostatic intraepithelial neoplasia[J].J Urol，2003，170（6 Pt 1）：2348-2351.
[10]	Kaufman JM，Graydon RJ.Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men[J].J Urol，2004，172（3）：920-922.
[11]	Agarwal PK，Oefelein MG.Testosterone replacement therapy after primary treatment for prostate cancer[J].J Urol，2005，173（2）：533-536.
[12]	Khera M，Grober ED，Najari B，et al.Testosterone replacement therapy following radical prostatectomy[J].J Sex Med，2009，6（4）：1165-1170.
[13]	Pastuszak AW，Pearlman AM，Lai WS，et al.Testosterone replacement therapy in patients with prostate cancer after radical prostatectomy[J].J Urol，2013，190（2）：639-644.
[14]	Pastuszak AW，Khanna A，Badhiwala N，et al.Testosterone therapy after radiation therapy for low，intermediate and high risk prostate cancer[J].J Urol，2015，194（5）：1271-1276.
[15]	Sarosdy MF.Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy[J].Cancer，2007，109（3）：536-541.
[16]	Morales A，Black AM，Emerson LE.Testosterone administration to men with testosterone deficiency syndrome after external beam radiotherapy for localized prostate cancer：preliminary observations[J].BJU Int，2009，103（1）：62-64.
[17]	Pastuszak AW，Pearlman AM，Godoy G，et al.Testosterone replacement therapy in the setting of prostate cancer treated with radiation[J].Int J Impot Res，2013，25（1）：24-28.
[18]	Balbontin FG，Moreno SA，Bley E，et al.Long-acting testosterone injections for treatment of testosterone deficiency after brachytherapy for prostate cancer[J].BJU Int，2014，114（1）：125-130.
[19]	Morgentaler A，Lipshultz LI，Bennett R，et al.Testosterone therapy in men with untreated prostate cancer[J].J Urol，2011，185（4）：1256-1260.
[20]	Kacker R，Hult M，San Francisco IF，et al.Can testosterone therapy be offered to men on active surveillance for prostate cancer？Preliminary results[J].Asian J Androl，2016，18（1）：16-20.
[21]	Fowler JE Jr，Whitmore WF Jr.The response of metastatic adenocarcinoma of the prostate to exogenous testosterone[J].J Urol，1981，126（3）：372-375.
[22]	Ferreira U，Leitao VA，Denardi F，et al.Intermittent androgen replacement for intense hypogonadism symptoms in castrated patients[J].Prostate Cancer Prostatic Dis，2006，9（1）：39-41.
[23]	Leibowitz RL，Dorff TB，Tucker S，et al.Testosterone replacement in prostate cancer survivors with hypogonadal symptoms[J].BJU Int，2010，105（10）：1397-1401.
[24]	Morgentaler A，Traish AM.Shifting the paradigm of testosterone and prostate cancer：the saturation model and the limits of androgen-dependent growth[J].Eur Urol，2009，55（2）：310-320.
[25]	Traish AM，Williams DF，Hoffman ND，et al.Validation of the exchange assay for the measurement of androgen receptors in human and dog prostates[J].Prog Clin Biol Res，1988，262：145-160.
[27]	Torres LO.Do we have enough evidences that make you safe to treat a man with hypogonadism one year after a radical prostatectomy for prostate cancer？ Opinion：YES[J].Int Braz J Urol，2018，44（1）：4-7.
[28]	Wroclawski ML，Heldwein FL.Do we have enough evidences that make you safe to treat a man with hypogonadism one year after a radical prostatectomy for prostate cancer？Opinion：Not Yet[J].Int Braz J Urol，2018，44（1）：8-13.